/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Rani Therapeutics Holdings Inc Share Price Today: Live Updates & Key Insights

Rani Therapeutics Holdings Inc share price today is $1.13, up -1.74%. The stock opened at $1.15 against the previous close of $1.15, with an intraday high of $1.15 and low of $1.105.

Rani Therapeutics Holdings Inc Share Price Chart

style
pb-0

Rani Therapeutics Holdings Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Rani Therapeutics Holdings Inc Share Price Performance

$1.13 -0.0174(-1.74%) RANI at 23 Mar 2026 02:58 PM Biotechnology
Lowest Today 1.105
Highest Today 1.15
Today’s Open 1.15
Prev. Close 1.15
52 Week High 3.87
52 Week Low 0.39
Day’s Range: Low 1.105 High 1.15
52-Week Range: Low 0.39 High 3.87
1 day return -
1 Week return -14.71
1 month return -12.4
3 month return -23.64
6 month return +114.7
1 year return -23.12
3 year return -81.07
5 year return -89.68
10 year return -

Rani Therapeutics Holdings Inc Institutional Holdings

RA Capital Management, LLC 8.71

Samsara BioCapital, LLC 8.71

Awm Investment Company Inc 6.66

SymBiosis Capital Partners, LLC 6.46

Vanguard Group Inc 5.24

Vanguard Total Stock Mkt Idx Inv 3.80

Siren, L.L.C. 2.05

Geode Capital Management, LLC 0.88

Vanguard Institutional Extnd Mkt Idx Tr 0.86

Nan Fung Group Holdings Ltd 0.51

683 Capital Management LLC 0.50

Fidelity Extended Market Index 0.41

Squarepoint Ops LLC 0.35

United Services Automobile Association 0.31

KESTRA PRIVATE WEALTH SERVICES, LLC 0.26

Blackrock Extended Mkt Fund CF 0.23

Takeda Pharmaceutical Co Ltd 0.21

Extended Equity Market Fund K 0.20

iShares Micro-Cap ETF 0.20

Millennium Management LLC 0.17

CWA Asset Management Group, LLC 0.15

Vifag 2002 SICAV 0.15

Qube Research & Technologies 0.15

Fidelity Total Market Index 0.14

BlackRock Inc 0.12

Bridgeway Capital Management, LLC 0.12

Bridgeway Ultra-Small Company Market 0.12

Fidelity Series Total Market Index 0.11

Spartan Extended Market Index Pool F 0.11

Northern Trust Corp 0.10

Abante Quant Value FI 0.10

NT Ext Equity Mkt Idx Fd - L 0.09

Farallon Capital Management, L.L.C. 0.08

NT Ext Equity Mkt Idx Fd - NL 0.08

iShares Nasdaq US Biotech ETF USD Acc 0.07

Vanguard Instl Ttl Stck Mkt Idx Tr 0.07

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.06

Spartan Total Market Index Pool G 0.06

Vanguard Balanced Index Inv 0.05

Fidelity Nasdaq Composite Index 0.04

Rani Therapeutics Holdings Inc Market Status

Strong Buy: 2

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Rani Therapeutics Holdings Inc Fundamentals

Market Cap 138.59 M

PB Ratio 23.866

PE Ratio 0.0

Enterprise Value 124.13 M

Total Assets 36.63 M

Volume 906751

Rani Therapeutics Holdings Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:2717000 2.7M, FY20:462000 0.5M, FY19:979000 1.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:2717000 2.7M, FY20:462000 0.5M, FY19:979000 1.0M

Annual Net worth FY23:-35658000 -35.7M, FY22:-63344000 -63.3M, FY21:-53088000 -53.1M, FY20:-16703000 -16.7M, FY19:-26597000 -26.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:172000 0.2M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-223000 -0.2M, Q2/2025:-240000 -0.2M, Q1/2025:172000 0.2M, Q3/2024:null 0.0M, Q2/2024:-255000 -0.3M

Quarterly Net worth Q3/2025:-5412000 -5.4M, Q2/2025:-6692000 -6.7M, Q1/2025:-7264000 -7.3M, Q3/2024:-6783000 -6.8M, Q2/2024:-6805000 -6.8M

About Rani Therapeutics Holdings Inc & investment objective

Company Information Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Organisation Biotechnology

Employees 105

Industry Biotechnology

CEO Mr. Talat Imran

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow

Rani Therapeutics Holdings Inc FAQs

What is the share price of Rani Therapeutics Holdings Inc today?

The current share price of Rani Therapeutics Holdings Inc is $1.13.

Can I buy Rani Therapeutics Holdings Inc shares in India?

Yes, Indian investors can buy Rani Therapeutics Holdings Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Rani Therapeutics Holdings Inc shares in India?

You can easily invest in Rani Therapeutics Holdings Inc shares from India by:

Can I buy fractional shares of Rani Therapeutics Holdings Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Rani Therapeutics Holdings Inc?

Rani Therapeutics Holdings Inc has a market cap of $138.59 M.

In which sector does Rani Therapeutics Holdings Inc belong?

Rani Therapeutics Holdings Inc operates in the Biotechnology sector.

What documents are required to invest in Rani Therapeutics Holdings Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Rani Therapeutics Holdings Inc?

The PE ratio of Rani Therapeutics Holdings Inc is N/A and the PB ratio is 23.87.